Winter 2024
The proteins strike back – Antibodies & more
Since the first antibody drug was approved back in 1986, monoclonal antibodies have emerged as the dominant class in the global US$417bn market for biologics. At the end of 2023, sales stood at more than US$230bn. However, after decades of development, new treatments are now hitting the market. Among them: improved versions of artificial bispecific antibodies, antibody-drug conjugates and other engineered proteins used in immunoreceptor-based therapies such as CAR-T and TCR-T cell therapies.
In this issue:
- Cover story – New proteins on the block
- Country alliance calls for launch of a European protein strategy
- Climate paralysis at COP29 in Baku
- Commission seeks industry input over Novo/Catalent deal
- Financing – the Italian way for start ups
- Interview: Thomas Lingelbach (Valneva SE) about the Valneva way
- 30 years of BIO-Europe – Spotlight Scandinavia
- IP – Unified Patent Court. quo vadis?
- Update of ongoing clinical trials, News from the Stock markets,
- Regional news, news from BIOTECH Austria, Society for Laboratory Automation and Screening (SLAS) and the Young European Biotech Network
- SPECIAL: Protein engineering
